HOVON 178 R/R WM Epco study

Study Design: A prospective phase I/II trial 

Patients: relapsed or refractory Waldenstrom’s macroglobulinemia

Treatment:  Epcoritamab

Status of the Study: Activated

Sponsor: HOVON, Josephine Vos

further informations